News

Ventripoint’s VMS Imaging System For Pulmonary Arterial Hypertension To Be Further Studied At New York’s Montefiore-Einstein Center

When diagnosing and treating diseases and conditions such as Pulmonary Arterial Hypertension, clear, accurate, and reliable imaging of the heart and surrounding tissues is essential for achieving the best outcomes for patients. A new imaging technology for PAH and other related indications is currently moving its way through testing, and…

PAH Therapy Macitentan Proven Effective In Recent SERAPHIN Study

A novel dual endothelin receptor antagonist (ERA), Macitentan, (manufactured by Actelion pharmaceuticals) had been approved for use against Pulmonary Arterial Hypertension (PAH) by the US FDA in October 2013. This came shortly after Actelion Pharma presented the results of its landmark clinical trial SERAPHIN (Study with Endothelin Receptor Antagonist…

FDA Postmarket Trial for PAH Treatment Bosentan Reveals Drug Does Not Reduce Time To Mortality Rates

Drug maker Actelion has indicated that the company’s Food and Drug Administration (FDA)–approved pulmonary arterial hypertension (PAH) drug Bosentan, which is also known under the brand names of Actelion and Tracleer, recently failed a key FDA postmarket test. The test, which was part of the postmarket COMPASS 2 trial, revealed that Bosentan did not reduce time…

New PAH Treatment Approved for Distribution in Japan

United Therapeutics Corporation has announced that Remodulin, a new treatment for pulmonary arterial hypertension (PAH) by subcutaneous and intravenous administration, has obtained a distribution permit in Japan from the country’s Ministry of Health, Labour and Welfare, the governmental body responsible for granting such approvals. Yu-Lun Lin, associate vice president and managing…